A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
University of California, Irvine
M.D. Anderson Cancer Center
Kyowa Kirin Co., Ltd.
AstraZeneca
University of Southern California
M.D. Anderson Cancer Center
Tesaro, Inc.
Memgen, Inc.
Trishula Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National Cancer Center, Japan
Hummingbird Bioscience
IGM Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
Johns Hopkins University
Biosplice Therapeutics, Inc.
InxMed (Shanghai) Co., Ltd.
Novartis
Sun Yat-sen University
Asan Medical Center
Ohio State University Comprehensive Cancer Center
Hutchmed
University of Arizona
Jiangsu HengRui Medicine Co., Ltd.
Mirati Therapeutics Inc.
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Emory University
Azaya Therapeutics, Inc.
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center